Using Calcitonin Gene-related Peptide Monoclonal Antibodies for Migraine Headache Treatment and Prevention

Novel drugs are available now for treating and preventing migraine attacks. Those new drugs have a special strategy to treat migraine by modifying the signaling of calcitonin gene- related peptide (CGRP) which is a strong neuropeptide released from the nerves. Monoclonal antibodies (mAbs) have been developed for targeting the CGRP pathway by binding the CGRP ligand (eptinezumab, galcanezumab fremanezumab,) or the CGRP receptor (erenumab). Recent studies show that mAbs have several advantages over small molecule antagonists, including high selectivity and reduced potential for drug–drug interactions. In this article we reviewed literature to assess whether mABs can be used for treatment of acute and chronic migraine safely compared to classical antimigraine agents.